Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth

Benign Prostatic Hyperplasia (BPH)

Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor-binding protein-3 reduces with increase in prostate size in benign prostatic hyperplasia

Aging Male.

Sreenivasulu K, Nandeesha H, Dorairajan LN, Rajappa M, Vinayagam V, Cherupanakkal C

doi: 10.1080/

Uro-Oncology

Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens

Prostate.

Ylitalo EB, Thysell E, Thellenberg-Karlsson C, Lundholm M, Widmark A, Bergh A, Josefsson A, Brattsand M, Wikström P

doi: 10.1002/pros.23935.

Uro-Oncology

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

J Urol.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW

doi: 10.1016/j.juro.2018.07.065.

Uro-Oncology

The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study

Prostate Cancer Prostatic Dis.

Goldberg H, Mohsin FK, Saskin R, Kulkarni GS, Berlin A, Kenk M, Wallis CJD, Chandrasekar T, Klaassen Z, Saarela O, Penn L, Alibhai SMH, Fleshner N

doi: 10.1038/s41391-020-0248-9.

Uro-Oncology

Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells

Prostate.

Kranzbühler B, Salemi S, Mortezavi A, Sulser T, Eberli D

doi: 10.1002/pros.23725.

HPV and Gynecologic Cancer

Dietary and circulating fatty acids and ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition

Cancer Epidemiol Biomarkers Prev.

Yammine S, Huybrechts I, Biessy C, Dossus L, Aglago EK, Naudin S, Ferrari P, Weiderpass E, Tjonneland A, Hansen L, Overvad K, Romana Mancini F, Boutron-Ruault MC, Kvaskoff M, Fortner RT, Kaaks R, Schulze MB, Boing H, Trichopoulou A, Karakatsani A, La Vecchia C, Benetou V, Masala G, Krogh V, Mattiello A, Macciotta A, Gram IT, Skeie G, Quiros Garcia JR, Agudo A, Sanchez-Perez MJ, Chirlaque MD, Ardanaz E, Gil L, Sartor H, Drake I, Idahl A, Lundin EA, Aune D, Ward HA, Merritt MA, Allen NE, Gunter MJ, Chajes V

doi: 10.1158/1055-9965.EPI-19-1477.

Uro-Oncology

Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer

Prostate.

Duijvesz D, Rodriguez-Blanco G, Hoogland AM, Verhoef EI, Dekker LJ, Roobol MJ, van Leenders GJLH, Luider TM, Jenster G

doi: 10.1002/pros.23813.

Uro-Oncology

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

Eur Urol.

Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Fransson AS, Leskinent MJ, Zeke M, Huttunen T, Ginman C, Investigators of the Scandinavian Prostate Cancer Study No. 13.

doi: 10.1016/j.eururo.2019.08.010.

Benign Prostatic Hyperplasia (BPH)

Influence of metabolic syndrome on the relationship between fatty acids and the selected parameters in men with benign prostatic hyperplasia

Aging (Albany NY).

Grzesiak K, Rył A, Ratajczak W, Stachowska E, Rotter I, Słojewski M, Sipak O, Walczakiewicz K, Laszczyńska M

doi: 10.18632/aging.101850.

Related content

Gene expression of insulin receptor, insulin-like growth factor increases and insulin-like growth factor-binding protein-3 reduces with increase in prostate size in benign prostatic hyperplasia

Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study

Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells

Dietary and circulating fatty acids and ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition

Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

Influence of metabolic syndrome on the relationship between fatty acids and the selected parameters in men with benign prostatic hyperplasia